Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a double-blind, two-arm, parallel-group, single-dose study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Celltrion
• Treatments: Trastuzumab

Criteria

Inclusion Criteria:

1. Healthy male subject

2. Subject voluntarily agrees to participate in this study

Exclusion Criteria:

1. Female.

2. Subject has a medical condition of disease including one or more.

3. Smoker